 Aduro Biotech, Inc. ADRO, a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes STING and A Proliferation Inducing Ligand APRIL pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the first patient with IgA nephropathy has been dosed in a Phase 1 clinical trial of BION-1301, an investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors. We are thrilled to have dosed the first patient with IgA nephropathy in the Phase 1 clinical study of our investigational anti-APRIL antibody, BION-1301, said Dimitry S.A. Nuyten, M.D., Ph.D., chief medical officer of Aduro. 